Archive | March, 2024

What Makes RESI Stand Out

7 Mar

By Cameron Hurlburt, Director of Business Development, LSN

The RESI South Conference is a hybrid event, with an in-person day on March 25th at the Whitley Atlanta Buckhead Hotel in Atlanta, GA, followed by two virtual days on March 26th and 27th. Life Science Nation expects 300+ life sciences startups, investors, and strategic partners to mingle for dynamic networking opportunities. The RESI South Partnering Platform opened on March 4th, connecting CEOs with 150+ early-stage investors. Tailored matchmaking in sectors like therapeutics, medical devices, diagnostics, and digital health awaits.

To learn more, please watch the RESI Overview Webinar hosted by our Chief Conference Officer and VP of Investor Research, Claire Jeong. In this 10-minute video, Claire provides an overview of the RESI conference series, explains what makes RESI South unique, and, most importantly, how the RESI conferences stand out from other partnering events.

Click the video to watch:

Register-now-button-new

RESI-South-2024_02062024.

Tips for Successful Partnering at RESI South 

7 Mar

By Caitlin Dolegowski, Marketing Manager, LSN

Caiti

Partnering conferences are an important part of an early-stage company’s journey to raising capital and achieving your fundraising goals. Life Science Nation (LSN) hosts the RESI conference series to provide partnering opportunities with investors and strategic partners. Additionally, LSN provides support to Founders and CEOs to get prepared for meetings by putting their best foot forward and prepping them with the tools necessary to get there. A key tool for making the most of our next conference, RESI South, is the RESI Survival Guide.

The RESI Survival Guide covers the 5 major steps to finding success at RESI:

  • Build a Comprehensive Partnering Profile
  • Develop your Executive Summary
  • Refine your Pitch Deck
  • Craft your Meeting Request Message
  • Outline a Follow-up Strategy

Read detailed explanations of each step and examples of executive summaries and meeting requests in the RESI Survival Guide.

Partnering for RESI South is LIVE as of Monday, March 4th. Make sure to set your schedules up and make time slots available and accept and send meeting requests to secure some meetings on your calendar.

LSN provides Partnering Tutorial webinars, you can signup to join the live webinar and participate in the Q&A on March 14, register here. The Partnering Tutorial is a terrific way to figure out how to navigate LSN’s RESI partnering system and learn insights on outreach strategy to secure investor and strategic partner meetings that are the right fit for you.

If you have any questions about getting prepared for RESI South or wish to have a consultation on your marketing materials, reach out to RESI@lifesciencenation.com and your Business Development representative will schedule some time with you to review. Registration is still open to attend RESI South, with options to attend both in-person and virtually. Happy Partnering!

RESI-South-2024_02062024.

Register-now-button-new

RESI-SPAIN-1100

Hot Investor Mandate: VC in Western Europe Invests Up to €20M in US & Europe-Based Devices, Diagnostics, and Digital Health Companies 

7 Mar

A venture capital firm headquartered in Western Europe invests in healthcare companies with typical check size ranging from €1-20M EUR, participating starting from the 2nd or 3rd rounds of financing until Series B. The firm focuses on companies in the U.S. or Europe. 
 
The firm invests in diagnostics, digital health, and medical devices. The firm does not invest in drugs, biotech, or therapeutics. The firm invests in companies in the in-development or clinical stages. The firm is indication-agnostic. 
 
The firm does not have specific management team requirements. The firm typically takes a board or observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: Investment Arm of International CDMO Invests in Early-Stage, Pre-IND Cell & Gene Therapy Companies Across the Globe

7 Mar

An investment vehicle of a world-class CDMO partner from concept to commercialization is looking for partnerships with cell and gene therapy related pipelines companies in Pre-Seed or Series A rounds with typical check sizes ranging from $500k-2M USD. The fund is open to global companies though prefers US-based companies. 
 
The firm is solely interested in cell and gene therapy related pipeline companies. The fund is indication-agnostic and is open to orphan diseases as well. Companies should be pre-IND and must have proof of concept. 
 
The firm may take a board or observer seat on a case-by-case basis. The fund requires founders to be full-time. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   
 

Hot Investor Mandate: US-Based Investment Firm Seeks Life Science Technologies in Areas of Neurology, Ophthalmology, Pulmonology

7 Mar

A venture capital firm founded in 2021 with headquarters in the US engages in Seed to Series C rounds, with preference in Series A-C, and focuses on solutions towards a variety of unmet medical needs. The firm is interested in precise, personalized and cost-effective medical technologies and services. While opportunistic regarding sectors, the firm has invested in companies including therapeutics, medtech, diagnostics, and digital health. Typical check sizes range from $3-7M USD on entry with some reserved for follow-ons. The firm can lead investments as well as join syndicates. Although U.S. companies are favored, the firm can invest globally. 
 
The firm is opportunistic in terms of life science and healthcare companies. The firm has a strong focus on ophthalmology, neurology, and pulmonology. For software, the firm has deep ties to the hospital innovation system and looks for opportunities that intersect the patient-provider interface. 
 
The firm typically requires taking a board or observer seat. The firm does not have specific company or management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: VC Firm Invests Up to $10M in Early-Stage Technologies Relevant to Precision & Personalized Medicine Based in US & Canada 

7 Mar

A VC invests in US and Canada-based companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD). 
 
The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area. 
 
The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Newer Entries →